Microbot Medical ( (MBOT) ) has shared an update.
Microbot Medical Inc. has announced the successful completion of patient enrollment and follow-up in its ACCESS-PVI human clinical trial, paving the way for a 510(k) submission to the FDA by the end of 2024. The company is fast-tracking its go-to-market strategy, aiming to build a commercial infrastructure and hire a healthcare executive to lead sales efforts, pending FDA clearance expected in the second quarter of 2025. This advancement highlights Microbot’s commitment to revolutionizing endovascular procedures with its LIBERTY® Endovascular Robotic Surgical System.
For detailed information about MBOT stock, go to TipRanks’ Stock Analysis page.
